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Background: Liver fibrosis is a consequence of chronic inflammation and is associated with protein changes
within the hepatocytes structure. In this study, we aimed to investigate if this is reflected by the urinary
proteome and can be explored to diagnose liver fibrosis in patients with chronic liver disease.
Methods: In a multicentre combined cross-sectional and prospective diagnostic test validation study, 129
patients with varying degrees of liver fibrosis and 223 controls without liver fibrosis were recruited. Addi-
tionally, 41 patients with no liver, but kidney fibrosis were included to evaluate interference with expres-
sions of kidney fibrosis. Urinary low molecular weight proteome was analysed by capillary electrophoresis
coupled to mass spectrometry (CE-MS) and a support vector machine marker model was established by
integration of peptide markers for liver fibrosis.
Findings: CE-MS enabled identification of 50 urinary peptides associated with liver fibrosis. When combined
into a classifier, LivFib-50, it separated patients with liver fibrosis (N = 31) from non-liver disease controls
(N = 123) in cross-sectional diagnostic phase II evaluation with an area under the curve (AUC) of 0.94 (95%
confidence intervals (CI): 0.890.97, p<0.0001). When adjusted for age, LivFib-50 demonstrated an AUC of
0.94 (95% CI: 0.890.97, p<0.0001) in chronic liver disease patients with (N = 19) or without (N = 17) liver
fibrosis progression. In this prospective diagnostic phase III validation set, age-adjusted LivFib-50 showed
84.2% sensitivity (95% CI: 60.496.6) and 82.4% specificity (95% CI: 56.696.2) for detection of liver fibrosis.
The sequence-identified peptides are mainly fragments of collagen chains, uromodulin and Na/K-transporting
ATPase subunit g . We also identified ten putative proteolytic cleavage sites, eight were specific for matrix
metallopeptidases and two for cathepsins.
Interpretation: In liver fibrosis, urinary peptides profiling offers potential diagnostic markers and leads to
discovery of proteolytic sites that could be targets for developing anti-fibrotic therapy.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Liver fibrosis
Capillary electrophoresis mass spectrometry
Urinary peptide marker
Diagnosiserology and Hepatology, Uni-
Clifford Bridge Road, Coventry
Bannaga).
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Liver fibrosis is the replacementof healthy liver tissue with a
scarred and fibrotic tissue. It is caused by a variety of hepatic insults
leading to hepatocellular death, followed by hepatic tissue degenera-
tion and regeneration [1]. In developed countries, the common
Research in context
Evidence before this study
Liver fibrosis develops slowly as a consequence of progressive
chronic inflammation, it has clinical and life-threatening impli-
cations to the patients affected. It is usually associated with
changes of proteins in the liver. Liver fibrosis can be silent in
patients and is often diagnosed late. Noninvasive diagnosis of
liver fibrosis in usual practice is still lacking, With the current
definitive tool being an invasive histological assessment via a
liver biopsy.
Added value of this study
In this study, the application of capillary electrophoresis mass
spectrometry enabled identification of 50 urinary peptides sig-
nificantly associated with liver fibrosis. Urinary peptides in liver
fibrosis were mainly fragments of collagen chains. Other dis-
covered urinary peptides included the homeostasis markers
such as uromodulin and Na/K-transporting ATPase subunit g .
These discovered peptides offer potential for diagnosis of liver
fibrosis using urine samples and enhance our understanding
about the pathogenesis of liver fibrosis and possible relevant
treatment options.
Implications of all the available evidence
Noninvasive urinary detection of liver fibrosis is an attractive
tool for diagnosing and/or screening patients at risk for liver
fibrosis in the primary care. Additionally, this study identified
eight proteolytic cleavage sites specific for matrix metallopepti-
dases and two cathepsins which are responsible for degrading
extracellular matrix proteins. These sites could be potential
therapeutic targets for antifibrotic therapy.
2 A.S. Bannaga et al. / EBioMedicine 62 (2020) 103083causes of liver fibrosis include alcohol abuse, hepatitis C virus (HCV)
infection and non-alcoholic steatohepatitis (NASH).
NASH is the severe form of non-alcoholic fatty liver disease
(NAFLD), for which patients with obesity, type 2 diabetes mellitus,
hyperlipidaemia and hypertension are predisposed [2]. Advanced
liver fibrosis may progressively result in liver cirrhosis (LC) and
chronic liver failure, and often requires liver transplantation as the
last curative treatment option.
Diagnosis and staging of liver fibrosis rely on histological assess-
ment of liver biopsies as the gold standard [35]. However, liver
biopsy is associated with discomfort for the patient and risk of com-
plications requiring post-biopsy care (e.g. intraperitoneal bleeding,
visceral perforation, and infections) or even death in rare cases [3].
Histological grading has further limitations, including variability due
to sampling (sampling error) and the experience of the investigator
[35].
Other diagnostic modalities used with increasing frequency in
clinical practice are vibration-controlled transient ultrasound elas-
tography (Fibroscan device; Echosens, Paris, France) which meas-
ures liver stiffness [57]. This approach has limitations since it does
not provide information about current fibrotic activity, whilst there
are also financial barriers to its use, as it carries a substantial initial
cost (about €100,000) and recurrent (for consumables and specialists
time) costs[7,8]. Additional tools used to diagnose advanced liver
fibrosis include surrogate markers related to liver function like AST/
ALT ratio and NAFLD fibrosis score. These markers appear to be only
useful in advanced liver fibrosis with poor performance at early
stages [9]. Recent research has focused not only on imaging tools, but
also on non-invasive biomarkers to determine the stage of liver
injury/fibrosis [46,10]. These efforts have led to the identification ofa plethora of possible serum biomarker candidates [4-6,1113].
Shortcomings unfortunately are common in these studies; several of
these involved a small number of patients and samples, thus potentially
suffering from clinical and therapeutic confounders, while they also
have not been decisively confirmed in independent and representative
prospective patient cohorts.
Morphologically liver fibrosis is characterized by an excessive
deposition of collagen-rich extracellular matrix (ECM) components in
the liver, which is mainly caused by the trans-differentiation of
hepatic stellate cells into collagen-producing cells and reduced deg-
radation of collagen fibrils [1,14]. Recent studies in the context of
chronic kidney disease and heart failure, we could demonstrate the
significant association of specific urinary collagen peptides with dis-
ease, and with fibrosis [15,16]. Based on these findings, we hypothe-
sized that specific urinary collagen-derived peptides may be valuable
in the detection of liver fibrosis. The hypothesis was tested in this
study, aimed at finding urinary peptides associated with liver fibrosis,
and in a second step combining these in a classifier that enables
non-invasive identification of patients with advanced fibrosis,
which can be silent with patients presenting late with complica-
tions. Urine is easily obtained and can be applied in primary care to
discover unidentified cases.
Capillary electrophoresis coupled to mass spectrometry (CE-MS)
has emerged in recent years as a hybrid technology using capillary
electrophoresis (CE) instead of liquid chromatography for sensitive
(1 fmol) and high-resolution low molecular weight protein and
peptide separation before mass spectrometry (MS) [17]. Notably, this
method enables profiling of the urinary proteomic content in a mass
range of 0.8 to 20 kilodalton (kDa) [17]. In addition, a database con-
taining currently more than 70,000 CE-MS datasets is available for
further in silico validation of findings [18].
In this study, we used CE-MS to search in the low molecular
weight proteome of urine from patients with NAFLD, NASH, LC and
hepatocellular carcinoma (HCC) for peptide markers sensitive for
liver fibrosis, and tested them for their use in staging and risk stratifi-
cation of liver fibrosis. The aim of this study was to explore value
diagnostic utility of urinary peptides in patients with liver fibrosis. To
reach this aim, our study design followed not a simple discovery and
validation approach, instead different steps of biomarker selection
were applied to ensure accurate diagnosis of liver fibrosis in patients
with liver disease. Also, it was based on two independent validation
cohorts, a cross-sectional cohort of patients with a long history of
liver fibrosis and a prospective cohort of liver disease patients under
continuous surveillance subdivided into groups with and without
clinical signs of liver fibrosis. The cross-sectional cohort was used
for performance evaluation and exploratory confounder analysis,
whereas the prospective cohort was used to evaluate clinical applica-
bility of the proteomic model and to determine important test
characteristics in an unbiased fashion in advance to the planning of
further prospective clinical studies.2. Methods
2.1. Ethics
Participants in the study were recruited between 2014 and 2019
from both University Hospital Coventry and Warwickshire, UK and
Hannover Medical School, Germany. In the UK, the study was
approved by both the Coventry and Warwickshire and North East-
York Research National Health Service Ethics Committees (Reference
numbers 09/H1211/38 and 19/NE/0213). In Germany, the study was
approved by the Ethics Committee of the Medical School Hannover
(Reference number: 901). Study conformed to the World Medical
Association Declaration of Helsinki, with all study participants
providing written informed consent.
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In the discovery phase, we prospectively recruited: (i) 19
patients with NAFLD; (ii) 9 patients with NASH, but without LC
manifestations; (iii) 13 patients with NASH and well established LC;
(iv) 19 patients with histologically confirmed cirrhosis not related
to NASH, mainly of viral or alcoholic origin; and (v) 19 patients with
HCC and LC.
Differential diagnosis of these patients was established by a
combination of liver ultrasound, Fibroscan and laboratory markers
(e.g. AST/PLT-ratio). Liver histology assessment was performed
when there was uncertainty of liver fibrosis. In order to reduce
confounding factors, we only included stable cirrhotic patients
from the liver outpatient clinics; none of whom had recently or
were currently receiving a course of antibiotics. Patients with type
2 diabetes or other gastrointestinal conditions (e.g. inflammatory
bowel disease or coeliac disease) were excluded.
Eighty-one normal individuals adjusted for age, gender and renal
function and without clinical or biochemical evidence of liver dis-
ease served as controls. These were selected from epidemiological
study populations ensuring absence of diabetes, heart disease,
hypertension, hyperlipidaemia and obesity. Composition of the liver
disease case and normal control groups together with the applied
exclusion criteria and adjusted demographic variables are presented
in Table 1.
In the validation phase, we recruited 123 normal control sub-
jects without evidence of liver disease and 19 patients with non-
fibrotic liver diseases of various aetiologies including two with
NAFLD, three with NASH and three with HCC as non-LC control
groups. Fifty patients with biopsy-proven LC of whom 11 had con-
comitant HCC, 13 benign biliary disorders, 9 chronic pancreatitis,
4 cholangiocarcinoma and 4 pancreatic cancer served as LC case
group. Thirty-one of these patients were selected cross-section-
ally based on their long-term clinical course and were used as an
initial patient set for performance evaluation of the LivFib-50
classification model followed by an additional confounder analy-
sis. The other 19 patients of this liver fibrosis case group with
much more diversified LC aetiologies and LC disease expressions
were recently enrolled and used for final prospective and unbi-
ased (by correction of confounders) evaluation of LivFib-50 classi-
fication values. Finally, a set of 41 patients with no liver, but
kidney fibrosis was included to evaluate potential interference of
the liver fibrosis-specific urinary peptide profile with expressions
of kidney fibrosis.2.3. Sample preparation
Urine was collected from all study participants in standard univer-
sal specimen containers (Newport, UK) and frozen to 80 °C, after
collection, for subsequent batch analysis. For proteomic analysis,
samples were prepared as previously described [19]. In brief, a
0.7 mL aliquot was thawed immediately before use and diluted with
0.7 mL 2 M urea, 10 mM NH4OH containing 0.02% Sodium Dodecyl
Sulfate. To remove proteins of higher molecular mass (e.g. albumin
and immunoglobulin G) the sample was filtered using a Centrisart
ultracentrifugation filter device (20 kDa molecular weight cut-off;
Sartorius, Goettingen, Germany) at 3000 rcf until 1.1 ml filtrate was
obtained.
Subsequently, the filtrate was loaded onto a PD-10 desalting col-
umn (GE Healthcare, M€unchen, Germany), and equilibrated in 0.01%
NH4OH in HPLC-grade H2O (Roth, Karlsruhe, Germany) in order to
decrease matrix effects by removing urea, electrolytes, and salts, and
also to enrich polypeptides. Finally, all samples were lyophilized,
stored at 4 °C, and resuspended in HPLC-grade H2O shortly before
CE-MS analysis.2.4. CE-MS analysis and data processing
CE-MS analysis was performed using a P/ACE MDQ capillary
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line
coupled to a Micro Time-of-Flight MS (Bruker Daltonic, Bremen,
Germany) [19]. The ESI sprayer (Agilent Technologies, Palo Alto,
USA) was grounded, and the ion spray interface potential was set
between 4.0 and 4.5 kV. Data acquisition and MS acquisition
methods were automatically controlled by the CE via contact-
close-relays. Spectra were accumulated every 3 s over a range of
m/z 350 to 3000. Details on accuracy, precision, selectivity, sensi-
tivity, stability, and reproducibility of the CE-MS method have
been established [19].
Mass spectral ion peaks, representing identical molecules at
different charge states, were deconvoluted into single masses using
MosaiquesVisu software [19]. For noise filtering, signals with z > 1
observed in a minimum of 3 consecutive spectra with a signal-to-
noise ratio of at least 4 were considered. MosaiquesVisu employs a
probabilistic clustering algorithm and uses both isotopic distribution
(for z  6) and conjugated masses for charge-state determination of
peptides/proteins.
The resulting peak list characterizes each polypeptide by its mass
and its migration time. Time-of-flight-MS data were calibrated utiliz-
ing 150 reference mass data points and 452 reference migration time
data points by applying global and local linear regression, respec-
tively. Ion signal intensity (amplitude) showed variability, mostly
due to different amounts of salt and peptides in the sample and were
normalized. Reference signals of 29 highly abundant peptides were
used as “internal standard” peptides for calibration using local linear
regression. This procedure was shown to be an easy and reliable
method to address both analytical and dilution variances in a single
calibration step [20]. The obtained peak list characterizes each poly-
peptide by its calibrated molecular mass [Da], calibrated CE migration
time [min] and normalized signal intensity.
All detected peptides were deposited, matched, and annotated in
a Microsoft SQL database allowing further statistical analysis. For
clustering, peptides in different samples were considered identical, if
mass deviation was <50 parts per million for small (<4000 Da) or 75
parts per million for larger peptides. Due to analyte diffusion effects,
CE peak widths increase with CE migration time. For data clustering,
this effect was considered by linearly increasing cluster widths over
the entire electropherogram (19 min to 45 min) from 2 to 5%.
2.5. Peptide sequencing
Peptide sequencing was carried out both on a Dionex Ultimate
3000 RSLS nanoflow system (Dionex, Camberly, UK) and a Beckman
CE/Orbitrap Q Exactive plus combination (Thermo Scientific, Wal-
tham, MA) [21]. Spectra files were analyzed with Proteome Discov-
erer 2.4 allowing a precursor mass tolerance of 5 ppm and a fragment
mass tolerance of 0.05 Da. This was followed by a search against the
UniProt human non-redundant database without any protease speci-
ficity or fixed modification. Oxidation of methionine and proline
were considered as variable modifications. Only sequences with high
confidence (Xcorr  1.9) and without unmodified cysteine were
accepted (due to the application of non-reducing conditions). A
strong correlation between peptide charge at the CE operating pH of
2 deduced from the number of basic amino acids in the annotated
peptide sequence and the migration time was used as another
criterion to prevent false sequence assignments [22].
2.6. Protease assessment
In silico protease assessment was performed using Proteasix
(www.proteasix.org), a web-based tool for investigation of proteo-
lytic events involved in naturally occurring peptide generation [23].
Table 1
Selected clinical and demographic characteristics of recruited study participants.
Patient group Discovery Validation Cross-sectional Validation Prospective Interference Testing
Study phase Normal controls
(Age/Gender-adj.)
Liver disease w/ fibrosis P* Normal controls Liver disease
w/ fibrosis
P* Liver disease
w/o fibrosis
Liver disease
w/ fibrosis
P* Kidney fibrosis
No patients, n 81 79 — 123 31 — 17 19 — 41
Age
mean (range), y
54
(2176)
56
(1879)
0.17 39
(2077)
56
(3382)
<0.0001 42
(2384)
64
(3186)
0.001 64
(1885)
Gender
female/male, n
30/51 34/45 0.52 62/61 5/26 0.0005 3/14 5/14 0.70 20/21
No peptides
mean (range), 1 £ 103
1.6
(0.93.2)
2.3
(0.64.0)
<0.0001 1.5
(0.82.7)
2.1
(0.84.1)
<0.0001 3.1
(1.54.5)
2.9
(1.14.6)
0.43 2.5
(1.24.5)
WBC
mean (range), 1 £ 103/mL
— 5
(113)
— — 7
(218)
— 6
(49)
7
(211)
0.49 —
Hb
mean (range), g/dL
— 13
(818)
— — 12
(1016)
— 14
(1116)
13
(916)
0.06 —
Plt
mean (range), 1 £ 109/L
236
(126326)
145
(25402)
<0.0001 238
(130490)
187
(51384)
0.017 261
(152470)
177
(69568)
0.05 —
INR
mean (range)
— 1.2
(0.92.0)
— — 1.2
(1.01.7)
— 1.0
(0.91.2)
1.1
(1.01.4)
0.002 —
TC
mean (range), mg/dL
207
(122312)
329
(93690)
0.0007 197
(119305)
185
(77321)
0.61 197
(155232)
378
(197540)
0.0003 272
(96561)
HDL
mean (range), mg/dL
56
(27105)
121
(9340)
<0.0001 57
(3497)
36
(2754)
0.003 49
(3170)
141
(70350)
0.0002 —
TG
mean (range), mg/dL
— 130
(46400)
— — 122
(48294)
— 266
(80549)
149
(55610)
0.12 —
AST
mean (range), U/L
21
(1365)
50
(13284)
<0.0001 21
(1246)
77
(20180)
<0.0001 44
(1690)
59
(20152)
0.40 —
ALT
mean (range), U/L
— 48
(11288)
— — 115
(221038)
— 45
(5246)
36
(1572)
0.33 —
ALP
mean (range), U/L
— 128
(44797)
— — 278
(71693)
— 88
(45358)
179
(44516)
0.0006 68
(19174)
GGT
mean (range), U/L
— 142
(15719)
— — 335
(491269)
— 133
(17374)
279
(22682)
0.11 —
Bilirubin
mean (range), mmol/L
— 25
(4163)
— — 48
(10210)
— 8
(314)
22
(465)
0.003 —
Albumin
mean (range), g/L
— 40
(2649)
— — 32
(1657)
— 46
(4051)
38
(2352)
0.001 —
AFP
mean (range), mg/L
— 429
(122,826)
— — 171
(11493)
— 17,330
(3103,965)
1414
(124,400)
0.36 —
* Difference between liver fibrosis cases and non-liver fibrosis controls included in the discovery, cross-sectional and prospective validation cohorts by two-tailed probability for continuous data and signifi-
cance level by Fisher exact test for categorical data.
Diagnosis was established by a combination of liver ultrasound, Fibroscan, laboratory markers, e.g. AST/PLT-ratio, and histology. Patients with type 2 diabetes or other gastrointestinal conditions (e.g. inflammatory
bowel disease or coeliac disease) were excluded. Controls were adjusted for age, gender and renal function and without clinical or biochemical evidence of liver disease served as controls. We ensured absence of
diabetes, heart disease, hypertension, hyperlipidemia and obesity.
Abbreviations: AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; Hb, hemoglobin; HDL, high density lipopro-
tein; INR, International Normalized Ratio; Plt, platelets; TC, total cholesterol; TG, triglycerides; WBC, white blood cells.
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minus of a peptide were retrieved from CutDB proteolytic event data-
base available at www.cutdb.burnham.org [24]. Protease activity was
assessed in the patient’s CE-MS peptide profiles to gain fold changes
between LC cases versus normal controls based on the average of
associated peptide intensities. This method is described in detail by
Voigtl€ander et al. [25].2.7. Tissue transcriptomic data analysis
Tissue transcriptomics data were retrieved from the NCBI Gene
Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/
geo/) and from the EMBL-EBI Expression Atlas (https://www.ebi.ac.
uk/gxa/home). This includes expression profiling data by array from
1) 22 patients with cirrhosis (LC) and 14 histologically normal livers
(GEO accession: GSE77627), 2) four biological replicates of histologi-
cally normal kidney and three biological replicates of histologically
normal liver of human origin (E-MTAB-2836, [26]), as well as 3) four
biological replicates of histologically normal kidney and four biologi-
cal replicates of histologically normal liver of human origin (E-MTAB-
5782, [27]). The GEO data sets were analysed with GEO2R (https://
www.ncbi.nlm.nih.gov/geo/geo2r/). Analysis was conducted using
default settings, with false discovery rate adjustment of p-values
based on the method by Benjamini & Hochberg [28]. For the presen-
tation of E-MTAB data, values are expressed in transcripts per million
(TPM) units.2.8. Statistical analysis
Clinical and demographic data, as well as peptide distributions in
the samples of the patients included in the different patient sub-
groups are presented either as mean § standard deviation or as per-
centage. For intergroup comparison, continuous data were compared
by Student's t-test or Mann Whitney rank-sum test, and categorical
data by Chi square or Fisher’s exact test after testing for normal distri-
bution. A two-sided p value < 0.05 was considered to be statistically
significant.
For peptide marker identification in the discovery phase of the
study, the distribution differences of the urinary peptides between
the patients with liver disease and normal controls were based on
natural logarithm transformed intensities and a non-parametric
Wilcoxon rank sum test. For correction of p-values due to multiple
testing the method by Benjamini and Hochberg was used [28].
Receiver-operating-characteristic (ROC) curves were generated
for the classification of the patient samples with the LivFib-50 classi-
fier. The ROC curve was obtained by plotting all sensitivity values
(true positive fraction) on the y axis against their equivalent (1-speci-
ficity) values (false positive fraction) on the x axis for all available
thresholds. The area under the ROC curve (AUC) was evaluated as it
provides a single measure of overall accuracy independent of any
threshold. Calculation of 95% confidence intervals (Cl) was based on
exact binomial calculations and the optimal balance of sensitivity
and specificity was determined based on the Youden index.
All statistical analyses were carried out using MedCalc version
12.7.5.0 (MedCalc Software; Mariakerke, Belgium).2.9. Role of funding source
This manuscript was supported by research grant from the medi-
cal and life sciences research fund (MLSRF) which was awarded to AB
to help with research consumables. It is charity that supports
research and education to enhance human health and had no role in
study design, data collection, data analyses, interpretation, or writing
of report.3. Results
3.1. Liver fibrosis peptide biomarker identification and support vector
machine model establishment
For the identification of urinary peptide markers associated with
fibrosis, we investigated the low molecular weight urine proteome
from 79 patients with chronic liver diseases and 81 age and gender-
matched normal subjects by CE-MS. Age- and gender-adjustment of
controls was implemented in the study design of the discovery phase
to ensure that only those peptides that are unaffected by age or
gender were selected as marker for liver fibrosis.
For age and gender adjustment, 81 normal controls were selected
from a pool of 204 normal controls by using the R-script “MatchIt”
[29], which conducts nearest neighbour matching with logistic
regression used to estimate the propensity score. The age of the 81
selected normal controls was subsequently compared with that of
the 79 liver fibrosis case patients by a Mann-Whitney rank sum test
and resulted in a p-value of 0.18. The difference in gender was proven
to be statistically insignificant (p = 0.63) by a Chi-squared test. For
renal function it was verified that all patients have no renal dysfunc-
tion at the date of urine collection as indicated by an eGFR-value
above 60 mL/min/1.73m2.
We specifically searched for those fibrosis markers showing a
gradual increase or decrease in their CE-MS-detected amplitude sig-
nals from normal over non-fibrotic NAFLD and NASH to LC. For this
purpose, we followed a three-step strategy which is schematically
presented in Fig. 1.
In the first selection step, we statistically compared the CE-MS
peptide profiles of the patients with liver diseases to those of the nor-
mal control subjects by a group-wise non-parametric Wilcoxon rank
sum test. From a total of 21,559 annotated peptides in the mass range
of 0.8 to 20 kDa, 854 peptides were identified with a frequency
threshold of 30% and p-values below 0.05. Out of these, 732 remained
significant after adjustment of the false discovery rate for multiple
testing by the Benjamini and Hochberg procedure [28]. The list of
peptides displaying differences in abundance between liver disease
and healthy control as generated in this first selection step is pre-
sented in Supplementary Table 1 together with their CE-MS proper-
ties and statistical characteristics. The amino acid sequence for those
of these peptides for which sequences could be assigned with high
confidence is also presented in Supplementary Table 1.
In the second selection step, we correlated the abundance of the
732 preselected peptides with a severity score of liver disease, assign-
ing 0 for normal controls, 1 for patients with NAFLD, 2 for patients
with NASH (both without signs of liver fibrosis), and 3 for patients
with LC to select peptides that appear associated with progression of
liver fibrosis. By selecting a threshold above 0.2 or below 0.2 for
Spearman rho correlation (FDR-adjusted p-values < 0.05), 500 out of
the 732 peptides selected in step 1 fulfilled also the selection criteria
from step 2. Out of the selected peptides, 198 showed negative corre-
lation and 302 were positively correlated to the severity scores of the
liver insult. The Spearman rho correlation factors of the 500 peptides
passing selection step 2 together with their FDR-adjusted p-values
are also presented in Supplementary Table 1. In this way, selection
step 2 was used as a first step to identify those liver disease-associ-
ated peptides that show a progression in their abundance depending
on the presence of liver fibrosis.
In the final biomarker selection step, we searched the list of the pre-
selected 500 peptides for those fibrosis associated markers showing a
strictly linear decrease or increase from normal controls over the NAFLD
and NASH patients to the LC-positive patients when applying a Kruskal-
Wallis rank sum test. This last, very stringent selection step reduced the
number of fibrosis grading markers to 50 peptides. The final list of fibro-
sis markers together with their statistical characteristics of all three
selection steps is presented in Supplementary Table 2.
Fig. 1. Study flow chart. A total of 391 patients was included in the discovery and validation phases of the LivFib-50 peptide marker model for the detection of progressive liver
fibrosis. Biomarker selection was carried out in three sequential steps resulting in 50 urinary peptides with differential and graded expression ranging from disease-free normal
individuals. over NAFLD and NASH patients without LC to patients with well-established LC. Combining the peptide markers to the LivFib-50 model was followed by a first evalua-
tion of the model’s classification performance and confounder analysis in patients with LC and normal controls. Since the classification factors significantly correlate with the age of
the patients, the LivFib-50 classification model was adjusted for age on these patient groups by logistic regression. In a final validation phase the age-adjusted LivFib-50 classification
model was validated in an independent group of patients with liver disease, with or without LC and interference of classification was tested in a set of patients with renal fibrosis,
but no liver fibrosis.
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support vector machine (SVM)-based peptide multi-marker panel
for non-invasive detection of liver fibrosis. The peptide marker
model was trained by SVM using a Radial Basis Function (RBF) ker-
nel using a cost C value of 9.7 and a gamma value of 0.00073 as pen-
alty settings. In combination, these two parameters control the
trade-off between allowing training errors and forcing rigid mar-
gins. After optimization of the SVM parameters, the peptide marker
pattern designated as LivFib-50 including the 50 peptides resulted
in an AUC of 0.95 and 95% (CI) in the range of 0.90 to 0.98
(p<0.0001) on the 19 NAFLD, 9 NASH and 51 LC (out of which 12 are
NASH-LC) patients and 81 normal control subjects in receiver oper-
ating characteristics analysis (ROC) after take-one-out total cross-
validation. The ROC curve and a table of ROC characteristics arepresented in Fig. 2A. As presented in the group-specific Box-and-
Whisker distribution plot of Fig. 2B, the established peptide marker
pattern not only allowed differentiation of the normal controls from
NAFLD, NASH and LC, but also the classification scores for NAFLD
and NASH-LC are significantly different, with higher values in the
case of LC.
3.2. Adjustment of the LivFib-50 peptide marker model for patient age
In a first validation phase, LivFib-50 was tested for generaliz-
ability on independent cross-sectional datasets of 31 patients with
LC and 123 normal controls. ROC analysis revealed an AUC of 0.94
(95% CI: 0.890.97, p<0.0001) in this diagnostic phase II testing.
Besides performance evaluation, correlation of LivFib-50 classification
Fig. 2A. ROC curve and ROC characteristics for the discovery set. Patients with NAFLD,
NASH, LC or HCC were treated as case group (N = 79) and were compared to non-dis-
eased age- and gender-matched normal controls (N = 81). Bootstrapping of the classifi-
cation results was performed by leave one out total cross-validation. Dotted lines
represent the upper and lower bounds of the confidence interval.
Fig. 3A. Distribution of classification scores of the LivFib-50 marker pattern in normal
liver and liver fibrosis groups of the first validation set of patients. The liver fibrosis
group (N = 31) was further divided into those with (N = 9) or without (N = 22) concom-
itant diabetes mellitus in order to evaluate the impact of diabetes mellitus on the Liv-
Fib-50 classification results. A post hoc test was performed for average rank
differences between the three different subgroups (each with p< 0.05) after a signifi-
cant result in the global Kruskal-Wallis test. The abbreviation n.s. indicates a non-sig-
nificant result.
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tics was done in this first validation cohort and not in the training
cohort since the former represents an independent patient group
free of any overfitting bias and thus without the need for any
bootstrapping. Confounder analysis revealed correlation of Liv-
Fib-50 classification to age (r = 0.43, p < 0.0001) as the only con-
founder with impact on the LivFib-50 classification result. Most
importantly and with the results shown in Fig. 3A, a potential
impact of diabetes mellitus (DM) was excluded by dividing the 31
patients with LC into those with (N = 9) and without (N = 22) DM
and by performing a global Kruskal Wallis analysis also including
the 123 patients without signs of liver disease. As a result of this
exploratory confounder analysis on this first validation set, anFig. 2B. Box and Whisker distribution plots for classification of the different patient
groups of the discovery set with the LivFib-50 model. A Kruskal-Wallis test was per-
formed for rank sum differences in the LivFib-50 classification scores and revealed sig-
nificant differences in post-hoc analysis between normal controls to all liver diseased
patient groups (p < 0.0001) as well as between patients with combined NASH and LC
(NASH-LC) compared to NASH without concomitant LC (p = 0.04).age-adjusted LivFib-50 model was constructed by logistic regression of
the LivFib-50 classification values and age on the basis of their odds
ratios of 27.54 (95% CI: 6.87110.33) and 1.16 (95% CI: 1.061.27)
resulting in a logit function for an age-adjusted LivFib-50 score ofFig. 3B. Classification of normal controls without clinical signs of liver disease (NC,
N = 123) and those with clinical manifestations of liver cirrhosis (LC, N = 31) with the
age-adjusted LivFib-50 peptide marker model in comparison to the proteomic model
without age adjustment and age alone. Age adjustment of the LivFib-50 peptide
marker model was performed using logistic regression. Significance P values for each
ROC curve were determined to be <0.0001.
Fig. 4A. ROC curve and ROC characteristics of the age-adjusted LivFib-50 peptide
marker model for patients with LC in the absence or presence of HCC (N = 19) com-
pared to non-fibrotic control patients (N = 17) in independent validation. Of note, the
three HCC patients without LC manifestations were treated as controls.
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presented in Fig. 3B, the age-adjusted LivFib-50 classification model
significantly improved classification performance relative to the Liv-
Fib-50 peptide marker model alone by an AUC increase of 0.027
(AUC = 0.96, p = 0.044) on the 31 LC cases in comparison to the 123
normal controls.Fig. 4B. Box and Whisker distribution plots for classification of the different patient groups o
set consists of patients without clinical signs of liver fibrosis (N = 17), patients with kidney fib3.3. Validation of the age-adjusted LivFib-50 classification model
For validation in a clinical setting of intended use, the age-
adjusted LivFib-50 model was tested in an independent set of 36 pro-
spectively collected chronic liver disease patients, 19 with and 17
without LC. This second validation set is essential for the diagnostic
test validation process in order to compensate for potential classifica-
tion bias by the fitted logistic regression model algorithm. As demon-
strated by an AUC of 0.91 and a 95% CI range of 0.76 to 0.98 at a
significance level of p<0.0001 (Fig. 4A), patients with LC are clearly
distinguishable in their LivFib-50 model scores from patients without
LC. Without age-adjustment the LivFib-50 model resulted in an AUC
of 0.87 (95% CI: 0.710.96, p<0.0001) on this second validation set
(data not shown). The positive (PPV) and negative (NPV) predictive
values were determined to be 67% (95% CI: 4285%) and 92% (95% CI:
8197%), respectively. Of note, we corrected the PPV and NPV for a
30% prevalence of liver fibrosis in chronic liver disease patients, since
our prospective validation cohort does not fully reflect the reported
value for this patient collective [30].
Applying the optimal classification threshold based on the Youden
index at 0.41, classification of this validation cohort resulted in a sen-
sitivity of 84.2% (95% CI: 60.496.6) and a specificity of 82.4% (95% CI:
56.696.2). As revealed by the Box-and-Whisker distribution plot of
LibFib-50 classification values in Fig. 4B, there is a clear separation
between the fibrotic and non-fibrotic patient groups irrespective of
concomitant HCC. A clear distinction from the case group is also
observed for patients with no liver, but kidney fibrosis as clearly
demonstrated by a specificity of 73% for LivFib-50 positivity in this
interference risk group.
3.4. Sequencing of liver fibrosis peptide markers reveal differential
urinary excretion of collagen chain fragments
We were able to obtain high confidence amino acid sequence
information for 22 of these 50 peptides. All liver fibrosis peptidef the validation set with the age-adjusted LivFib-50 classification model. The validation
rosis (N = 41) and patients with LC or fibrosis (N = 19).
Table 2
Amino acid alignment of all sequence-identified naturally occurring urinary peptides included in the LivFib-50 peptide marker model due to
their graded association with progressive liver fibrosis. Peptide markers are for the most part overlapping fragments derived from the triple
helical region of the collagen a1(I) chain. Opposite regulation of overlapping fragments might be attributed to changes in the activity of extra-
cellular matrix degrading proteases during fibrosis progression.
Peptide IDy Sequencez AAx Regulation in
liver fibrosisǁ
Protein name
6546 PpGPpGKNGDDGEAGKP 222238 # Collagen a1(I)
chain (COL1A1)9627 PpGPpGKNGDDGEAGKpGRp 222241 #
13,021 LDGAKGDAGpAGpKGEpGSpGENGApG 273299 "
5810 PpGEAGKpGEQGVpGD 651666 "
3793 GEAGKPGEQGVPGD 653666 #
8462 GANGApGNDGAKGDAGApGApG 698719 #
4419 ApGDRGEpGPpGPAG 798812 #
2136 GDRGEpGPpGPA 800811 #
14,801 GPpGADGQPGAKGEpGDAGAKGDAGpPGPAGP 815846 #
11,753 GADGQpGAKGEPGDAGAKGDAGPpGP 818843 "
13,342 GADGQpGAKGEpGDAGAKGDAGpPGPAGP 818846 "
10,953 DGQpGAKGEpGDAGAKGDAGPpGP 820843 "
3079 EKGSpGADGpAGAP 933946 "
13,730 AGPpGAPGApGAPGPVGPAGKSGDRGETGP 10421071 "
11,744 LQGLpGTGGPpGENGKpGEpGPKG 640663 # Collagen a1(III)
chain (COL3A1)9061 GApGApGGKGDAGApGERGPpG 666687 "
16,811 GERGSpGGpGAAGFpGARGLpGpPGSNGNPGPpGp 861895 "
13,779 DDILASPPRLPEPQPYPGAPHHSS 15341557 " Collagen a1(XVIII) chain (COL18A1)
16,419 EAGRDGNpGNDGPpGRDGQpGHkGERGYPG 923952 # Collagen a2(I)
chain (COL1A2)
2740 YLGGSPKGDVDP 516 " Na/K-transporting
ATPase subunit g (FXYD2)
5833 SGSVIDQSRVLNLGP 589603 # Uromodulin (UMOD)
5241 DQSRVLNLGPITR 594606 #
y Peptide identification numbers.
z Lower case p and k indicates hydroxyproline and hydroxylysine.
x Amino acid positions according to UniProt Knowledge Base numbering.
ǁ Regulation determined sequentially from normal controls over NAFLD and NASH (all without clinical signs of liver cirrhosis) to clinically
well-documented liver cirrhosis by the Kruskal-Wallis rank sum test.
Abbreviations: AA, amino acid sequence; Da, Dalton; MS, mass spectrometry; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic
steatohepatitis.
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sequence are presented in Table 2. These peptides are mainly frag-
ments of collagen a1(I) (n = 14) and five other collagen fragments.
Of these, 10 showed increased and nine showed reduced excretion
during fibrosis. Other peptides are derived from the renal homeosta-
sis proteins such as uromodulin (n = 2) and Na/K-transporting ATPase
subunit g (n = 1), with decreased urinary levels in the former and
increased urinary levels in the latter case.
Collagen fragments were reported as biomarkers for a variety of
other pathologies, especially for association with fibrosis in kidney
disease and possibly heart failure. To estimate a potential interfer-
ence, we have investigated the degree of overlap with the chronic
kidney disease-specific classifier CKD273 [31] and the heart failure-
specific classifier HF1 [32]. As a result, an overlap of six peptides
(12%) was detected for CKD273. Three (6%) thereof had the same
direction of regulation compared to controls. In the case of HF1, there
was an overlap of five peptides (10%) of which four (8%) showed the
same trend. Based on these results, interference of LivFib-50 with
CKD273 and HF1 is estimated as low, which will however be further
investigated in subsequent studies.
Following the hypothesis that naturally occurring peptides for the
most part arise from proteolytical degradation of their parent pro-
teins, we searched for observed protease cleavage sites in the CutDB
database on the basis of the octamer amino acid sequence motifs
around the N- and C-terminal ends of the 22 sequence-identified
fibrosis peptide markers. As presented in Supplementary Table 3, we
identified ten putative proteolytic cleavage sites, eight with specific-
ity for matrix metallopeptidases and two for cathepsins. Protease
activity was subsequently assessed in the patient’s CE-MS peptide
profiles based on the average of associated peptide intensities in the
31 LC cases compared to the 123 normal controls of the cross-sec-
tional validation set. This analysis revealed a fold change (FC) in theactivity between LC cases and normal controls of 0.86 (p = 0.0005) for
MMP2, 0.89 (p = 0.0016) for MMP3, 0.56 (p<0.0001) for MMP13, 0.90
(p = 0.0034) for MMP14 and 0.74 (p<0.0001) for CTSB. All other pro-
teases listed in Supplementary Table 3 were not identified as being
significant by this kind of analysis.
Next, we analyzed tissue transcriptomics data of 22 cirrhotic and
14 normal human livers retrieved from the NCBI GEO database
(GSE77627) to compare it with our proteomic results. As presented
in Supplementary Table 4, we identified significant differences in
gene expression levels between cirrhotic and normal tissue for the
collagen chains COL1A2 (FC: 0.66, p = 0.04) and COL3A1 (FC: 0.28,
p = 5.26E-06), both with a decreased fold change ratio in LC,
whereas COL18A1 (FC: 1.49, p = 0.026) showed increased expression
in LC. For the protease CTSB a significant decrease in its expression
levels was found, with the fold change in LC being 0.45 (p = 4.31E-
04). The relevant MMP’s demonstrate an increase in expression, as
in the case of MMP2 (FC: 3.08, p = 0.002), or no significant expres-
sion differences between cirrhotic and normal livers, as in the case
of the MMP’s 3, 13 and 14. Finally, as shown for two independent
transcriptomic data sets in Supplementary Figure 1, expression lev-
els of COL1A1, COL3A1 and COL18A1 are higher, whereas those of
COL1A2 are lower in histologically normal livers than histologically
normal kidneys of humans.
4. Discussion
This is the first study using CE-MS to identify urinary peptides as
biomarkers for liver fibrosis. The findings reported here demonstrate
feasibility to identify specific peptide markers significantly associated
with liver fibrosis, which, can be combined into a multi-marker panel
for accurate detection of liver fibrosis, irrespective of other comorbid-
ities. Our initial hypothesis that the transition from a healthy liver
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characterized by fibrosis which displays in urinary collagen frag-
ments could be verified in this study [1,2,33]. To select specific fibro-
sis marker(s), our search strategy for urinary biomarkers was not
restricted to a statistical group comparison of peptide distributions in
patients with NAFLD and NASH compared to normal individuals, but
also extended to patients with LC (both alcohol and non-alcohol aeti-
ology). Aside from this group-wise comparison, our fibrosis marker
search strategy was further adapted to peptides that showed gradual
differences in their excretion profiles between normal liver states,
NAFLD, NASH and LC, representing groups with none, mild, moderate
to advanced stages of fibrosis. Validation of the findings was per-
formed in a different set of samples, further strengthening the
validity of our findings.
Even after applying highly stringent criteria, CE-MS-based urinary
proteome analysis, enabled the definition of a set of 50 naturally
occurring peptides in the molecular mass range of 0.8 to 20 kDa that
showed significant differences in their excretion profiles with high
confidence (due to adjustment of p-values by the Benjamini and
Hochberg procedure [28]) between normal subjects and patients
with NAFLD, NASH or LC. Moreover, these peptides are correlated
with the severity of liver injury from normal liver state over NAFLD
and NASH to LC, as demonstrated by Spearman Rho correlation fac-
tors above 0.2 or below 0.2.
The amino acid sequence could be resolved from 22 of these 50
peptides. Reasons for not retrieving the amino acid sequence for all
peptides include the inability to identify all possible post-transla-
tional modifications, e.g. due to high glycan heterogeneity [34], and
resistance of the peptide to its total fragmentation even at high colli-
sion energies in tandem mass spectrometry. This is of no relevance
for the diagnostic use of the peptide marker model, as indicated for
example by clinical application of a combined bile and urine prote-
ome test for cholangiocarcinoma diagnosis based on similar peptide
marker models [3537], and is based on the fact that the peptide
markers are clearly defined in the CE-MS as the device for operating
the diagnostic test by their molecular mass and by their capillary
electrophoresis migration time.
In liver fibrosis, normal hepatic tissue is replaced by connective
tissue. Morphologically liver fibrosis is characterized by an excessive
deposition of collagen-rich ECM components in the liver, which is
thought to be mainly caused by the trans-differentiation of hepatic
stellate cells into collagen-producing cells and reduced degradation
of collagen fibrils [1,14]. Since urine in its low molecular weight pro-
tein composition consists to a large degree of collagen fragments,
partially arising from glomerular filtration and endosomal-exosomal
passage of blood circulating collagen fragments, we hypothesize that
progressive fibrosis can be detected by the profiling of the urinary
low molecular weight proteome.
A further advantage of the approach chosen is the ability to adjust
for confounders based on additional data available from the CE-MS
database. As such, we could also test the specificity of the age-
adjusted LivFib-50 peptide model for liver fibrosis. When investigat-
ing data from patients with chronic kidney disease and kidney fibro-
sis, the later defined as  2.5% of fibrosis per total tissue area, 30 out
of 41 (73%) of these patients scored negative for liver fibrosis. This is
in line with the finding, that no impact of DM on LivFib-50 classifica-
tion was observed in a global Kruskal-Wallis rank sum test when sub-
dividing the LC patients of our cross-sectional study cohort into those
with or without DM.
Not unexpectedly, due to the impact of dysregulated ECM remod-
eling on the progression of liver fibrosis, sequencing of the peptide
markers included in the LivFib-50 classification model revealed a pre-
dominant abundance of peptides derived from fibrillar collagen
chains, and particularly from collagen a1(I) (COL1A1) and collagen
a1(III) (COL3A1). Amino acid alignment of the 14 COL1A1 peptides
to the linear protein sequence revealed that some of the peptides areoverlapping fragments of certain areas within the triple helical
COL1A1 region. In respect to the differences in peptide distributions
between patients with liver disease and normal controls, even over-
lapping peptides demonstrate opposite regulation. The restriction of
the peptide markers to certain protein regions and the non-direc-
tional type of regulation of the COL1A1 peptide markers might be
explained by sites of increased proteolytical accessibility and changes
in the activity of ECM degrading proteases during fibrosis progres-
sion. In this respect, the comparison of the octamer amino acid motifs
surrounding the N- and C-terminal ends of the 50 fibrosis peptide
markers with already reported proteolytic cleavage sites reported in
the CutDB, proteolytic event database[24] was performed and
resulted in the identification of ten putative proteolytic cleavage
sites, eight specific for matrix metallopeptidases and two for cathe-
psins [38,39].
Our results on proteases predicted to be responsible for cleavage
of our collagen markers are in agreement with the role of matrix met-
allopeptidases and cathepsins in liver fibrotic disease processes
[40,41]. Both are essential together with their tissue inhibitors of
metallopeptidases (TIMP) counterparts in maintaining the structure
of the hepatic extracellular matrix. Their normal function becomes
impaired in the presence of chronic liver inflammation leading to
fibrogenesis.
To provide further evidence, we have compared our findings with
tissue transcriptomics data of human cirrhotic and normal livers and
found evidence for differential regulation of the targeted collagen
chains and predicted proteases also in liver tissue. It must be stated,
however, that the regulation of protease activity and the degradation
of the ECM leading to the release of endogenous collagen peptides
into circulation and then into urine is much more complex than sim-
ply explained by changes in tissue gene expression levels. To deter-
mine the origin of the collagen peptide markers, we compared gene
expression levels of their collagen precursors in normal livers versus
normal kidneys [26,27] and found higher expression levels of
COL1A1, COL3A1 and COL18A1 in the liver than in the kidney.
Together with the observation that a significant part of the urinary
collagen peptides is derived from extrarenal origin [42], this provides
evidence that the identified collagen peptide markers are derived
from fibrotic processes in the liver.
Finally, when the activity of the predicted proteases was assessed
based on the associated peptide marker expressions in the patient’s CE-
MS peptide profiles [25], significance could be reached for the MMP’s 2,
3, 13 and 14, as well as CTSB. Since for all of these proteases a decrease
in activity was predicted in the case of LC, this leads us to the hypothesis
based on literature findings [43,44] that mainly TIMP-2 might be the
inducer and/or hepatorenal connector leading to the observed changes
associated with liver fibrosis in the urinary peptidome.
Recently, diagnostic tests for cardiac fibrosis were proposed on
the immunological detection of COL1A1 fragments in human serum.
The tests are based on assessment of the carboxy-terminal propep-
tide (PICP) and the carboxy-terminal telopeptide (CITP) of COL1A1
[45]. Similarly, the LITMUS consortium reported the development of
the two diagnostic panels FIBC3 and ABC3D both based on the detec-
tion of plasma levels of a PRO-C3 collagen neo-epitope for diagnosis
and quantification of advanced liver fibrosis in patients with NAFLD
[46]. These recent developments underpin the significance of circu-
lating collagen fragments in non-invasive fibrosis testing. The LivFib-
50 peptide marker model reported here is based on simultaneous
detection of 50 urinary peptides by mass spectrometry. Such a multi-
plexed analysis has the advantage over single biomarker detection
and it better compensates for biological and analytical variances
making the diagnostic test more robust against interferences and var-
iances caused by a complex biological matrix. Mass spectrometry in
addition allows direct detection of the analyte in the sample and thus
eliminates the need for antigen binding reagents with the potential
to introduce bias by antigen cross reactivity.
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higher selectivity: each peptide is detected based on its exact mass,
while antibodies detect an epitope that may be present in multiple
similar peptides, thereby severely compromising selectivity and
accuracy. Due to its wide and adjustable measurement range and its
independence from a sieving matrix and the requirement for contin-
uous adaptation of electrospray conditions, CE-MS combined with
stringent calibration and proteomic data normalization procedures is
highly adapted for the use in routine clinical practice.
Over the last years, this was demonstrated in technical reports
[19,20] and large-scale prospective and/or longitudinal clinical stud-
ies [4751]. Recently, the value and applicability of CE-MS in the
early detection of chronic kidney disease in a large multicentric ran-
domized controlled trial has been demonstrated. In this respect, our
results demonstrate that with further validation in larger prospective
studies, urinary peptide detection can extend to screening in the pri-
mary care for liver fibrosis, which is lacking at present. This approach
also offers insights into the pathophysiology of liver fibrosis and rele-
vant peptidases involved in the hepatic ECM remodeling as well as
potential antifibrotic therapeutic interventions in liver fibrosis.
Our study was limited with the variable degrees of liver fibrosis in
patients recruited, hence our markers are indicative of presence of
liver fibrosis rather than the stage of it. Development of classifiers for
staging requires further investigation and validation against different
histological grades of liver fibrosis. Nonetheless, these markers relate
to changes within an individual patient rather than being a surrogate
indication of liver function.
Another limitation of this study is that not all peptides included in
the LivFib-50 model could be sequenced. In CE-MS, a peptide is iden-
tified simply by its physicochemical characteristics, namely number
of positive charges at pH 2 and molecular mass. This is sufficient for
its definite detection in a patient sample. Nevertheless, identification
of endogenous peptide markers is desirable to understand the patho-
physiological context behind their altered expression. Sequence
identification is however challenging, most likely due to unknown
post-translational modifications or resistance of larger peptides to
fragmentation during the MS/MS. As such, sequence information can
frequently not be assigned with the high confidence level. In the case
where only the 21 sequenced peptides of the LivFib-50 model were
used for classification of patients from the first validation set, an AUC
of 0.84 (95% CI: 0.780.90, p<0.0001) was received under identical
SVM settings, which is statistically inferior (p = 0.014 for the differ-
ence in areas) to that of 0.94 (95% CI: 0.890.97, p<0.0001) received
with all LivFib-50 peptide markers. Thus, also the peptides for which
the sequence could not be resolved until to date should be kept in
the classification model.
Our findings indicate that specific biomarkers of liver fibrosis in
the urine of patients with different liver diseases and different grades
of liver injury/fibrosis exist. These urinary peptide markers can be
combined into a multivariate model with high discriminatory poten-
tial. Further validation that qualifies the selected peptide markers for
liver fibrosis and thorough evaluation of the established peptide
multi-marker model from this initial study appear warranted to
assess their exact value in predicting and staging liver fibrosis.
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